CL2016000400A1 - Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. - Google Patents
Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.Info
- Publication number
- CL2016000400A1 CL2016000400A1 CL2016000400A CL2016000400A CL2016000400A1 CL 2016000400 A1 CL2016000400 A1 CL 2016000400A1 CL 2016000400 A CL2016000400 A CL 2016000400A CL 2016000400 A CL2016000400 A CL 2016000400A CL 2016000400 A1 CL2016000400 A1 CL 2016000400A1
- Authority
- CL
- Chile
- Prior art keywords
- acute
- diaminopyridine
- modulators
- receptor
- sub
- Prior art date
Links
- 230000001154 acute effect Effects 0.000 title abstract 2
- 206010011224 Cough Diseases 0.000 title 1
- 208000013116 chronic cough Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869174P | 2013-08-23 | 2013-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000400A1 true CL2016000400A1 (es) | 2017-01-20 |
Family
ID=52480919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000400A CL2016000400A1 (es) | 2013-08-23 | 2016-02-22 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
| CL2018002138A CL2018002138A1 (es) | 2013-08-23 | 2018-08-08 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400) |
| CL2018002137A CL2018002137A1 (es) | 2013-08-23 | 2018-08-08 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400) |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002138A CL2018002138A1 (es) | 2013-08-23 | 2018-08-08 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400) |
| CL2018002137A CL2018002137A1 (es) | 2013-08-23 | 2018-08-08 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400) |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9284279B2 (enExample) |
| EP (2) | EP3865134A1 (enExample) |
| JP (3) | JP6546592B2 (enExample) |
| KR (1) | KR102196885B1 (enExample) |
| CN (1) | CN105682659B (enExample) |
| AU (1) | AU2014308606B2 (enExample) |
| CA (1) | CA2921395C (enExample) |
| CL (3) | CL2016000400A1 (enExample) |
| CR (1) | CR20160093A (enExample) |
| IL (1) | IL244131B (enExample) |
| MX (1) | MX367657B (enExample) |
| MY (1) | MY195728A (enExample) |
| NI (1) | NI201600029A (enExample) |
| NZ (1) | NZ716977A (enExample) |
| PE (1) | PE20160431A1 (enExample) |
| PH (1) | PH12016500357A1 (enExample) |
| RU (1) | RU2650118C2 (enExample) |
| SG (1) | SG11201601145RA (enExample) |
| UA (1) | UA118851C2 (enExample) |
| WO (1) | WO2015027212A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6546592B2 (ja) * | 2013-08-23 | 2019-07-17 | アファレント ファーマシューティカルズ インコーポレイテッド | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
| EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
| EP3653207A1 (en) | 2014-02-10 | 2020-05-20 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| HUE061764T2 (hu) * | 2015-09-29 | 2023-08-28 | Afferent Pharmaceuticals Inc | Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10662162B2 (en) * | 2016-03-25 | 2020-05-26 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
| WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
| EP3554504B1 (en) | 2016-12-15 | 2022-10-26 | Afferent Pharmaceuticals Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses thereof |
| RU2021120039A (ru) * | 2016-12-20 | 2021-08-03 | Эфферент Фармасьютикалз, Инк. | Кристаллические соли и полиморфы антагониста p2x3 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| CA3093409A1 (en) | 2018-03-15 | 2019-09-19 | Danmir Therapeutics, Llc | 3",5"-dialkoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and pharmaceutical uses thereof |
| CA3096505A1 (en) * | 2018-04-23 | 2019-10-31 | Merck Sharp & Dohme Corp. | Novel process for synthesis of a phenoxy diaminopyrimidine compound |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| JP2021523919A (ja) * | 2018-05-15 | 2021-09-09 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| MX2021000908A (es) | 2018-07-23 | 2021-06-08 | Trevi Therapeutics Inc | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. |
| PL3862000T3 (pl) * | 2018-10-05 | 2024-03-18 | Shionogi & Co., Ltd | Lek na przewlekły kaszel |
| WO2020174283A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| US20220211703A1 (en) * | 2019-04-30 | 2022-07-07 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| ES3056709T3 (en) * | 2019-04-30 | 2026-02-24 | Beijing Tide Pharmaceutical Co Ltd | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
| MX2022002941A (es) | 2019-09-19 | 2022-04-06 | Shionogi & Co | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. |
| MX2022008554A (es) | 2020-01-10 | 2022-08-10 | Trevi Therapeutics Inc | Metodos de administracion de nalbufina. |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| WO2024080126A1 (ja) | 2022-10-12 | 2024-04-18 | ソフトバンクグループ株式会社 | 情報処理システム、情報処理装置、制御装置及びプログラム |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1725540T5 (da) * | 2004-03-05 | 2012-10-22 | Hoffmann La Roche | Diaminopyrimidiner som p2x3- og p2x2/3-antagonister |
| JP2008507368A (ja) * | 2004-07-22 | 2008-03-13 | デュスカ サイエンティフィック カンパニー | 肺疾患を診断、モニタリングおよび治療するための方法 |
| ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| CN101296907B (zh) | 2005-09-01 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类 |
| WO2007025898A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Process for synthesis of aryloxy diaminopyrimidines |
| CA2620034C (en) * | 2005-09-01 | 2013-10-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP2079713B1 (en) * | 2006-10-04 | 2014-04-16 | F. Hoffmann-La Roche AG | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| US9550763B2 (en) * | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
| JP6546592B2 (ja) | 2013-08-23 | 2019-07-17 | アファレント ファーマシューティカルズ インコーポレイテッド | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
| US9133647B2 (en) * | 2013-10-11 | 2015-09-15 | Nexkey, Inc. | NFC or BLE based contactless lock with charge monitoring of its energy storage |
-
2014
- 2014-08-22 JP JP2016536497A patent/JP6546592B2/ja active Active
- 2014-08-22 PE PE2016000285A patent/PE20160431A1/es unknown
- 2014-08-22 EP EP21159088.0A patent/EP3865134A1/en active Pending
- 2014-08-22 EP EP14838254.2A patent/EP3035932A4/en not_active Withdrawn
- 2014-08-22 NZ NZ716977A patent/NZ716977A/en unknown
- 2014-08-22 WO PCT/US2014/052389 patent/WO2015027212A1/en not_active Ceased
- 2014-08-22 UA UAA201601740A patent/UA118851C2/uk unknown
- 2014-08-22 CR CR20160093A patent/CR20160093A/es unknown
- 2014-08-22 US US14/466,713 patent/US9284279B2/en active Active
- 2014-08-22 CN CN201480058491.3A patent/CN105682659B/zh active Active
- 2014-08-22 CA CA2921395A patent/CA2921395C/en active Active
- 2014-08-22 SG SG11201601145RA patent/SG11201601145RA/en unknown
- 2014-08-22 RU RU2016105581A patent/RU2650118C2/ru active
- 2014-08-22 MY MYPI2016000327A patent/MY195728A/en unknown
- 2014-08-22 KR KR1020167007167A patent/KR102196885B1/ko active Active
- 2014-08-22 AU AU2014308606A patent/AU2014308606B2/en active Active
- 2014-08-22 MX MX2016002289A patent/MX367657B/es active IP Right Grant
-
2016
- 2016-02-02 US US15/013,798 patent/US9724346B2/en active Active
- 2016-02-15 IL IL244131A patent/IL244131B/en active IP Right Grant
- 2016-02-22 CL CL2016000400A patent/CL2016000400A1/es unknown
- 2016-02-22 NI NI201600029A patent/NI201600029A/es unknown
- 2016-02-23 PH PH12016500357A patent/PH12016500357A1/en unknown
-
2017
- 2017-08-01 US US15/665,595 patent/US10206922B2/en active Active
-
2018
- 2018-08-08 CL CL2018002138A patent/CL2018002138A1/es unknown
- 2018-08-08 CL CL2018002137A patent/CL2018002137A1/es unknown
-
2019
- 2019-03-25 JP JP2019055849A patent/JP7210348B2/ja active Active
-
2022
- 2022-10-18 JP JP2022166618A patent/JP7423725B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000400A1 (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. | |
| MX2022014331A (es) | Metodos y composiciones para el tratamiento de trastornos epilepticos. | |
| CL2018001181A1 (es) | Inhibidores de ret | |
| UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| MX2017005457A (es) | Metodos y compuestos agonistas de gip. | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| MX390517B (es) | Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion. | |
| MX2017003359A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2016012530A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. | |
| MX2021011939A (es) | Compuestos neuroactivos y metodos de uso de los mismos. | |
| MX2017001553A (es) | Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. | |
| EA201891626A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
| BR112017011168A2 (pt) | medicamentos para retardar a doença de parkinson |